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Summary 
Uncovering mechanisms that control immune responses in the resolution of bacterial 
infections is critical for the development of new therapeutic strategies that resolve 
infectious-inflammation without unwanted side effects. Herein, we found that disruption 
of the vagal system in mice delayed resolution of Escherichia coli infection. Dissection of 
the right vagus decreased peritoneal Group 3 innate lymphoid cell (ILC3) numbers and 
altered peritoneal macrophage responses. Vagotomy resulted in an inflammatory 
peritoneal lipid mediator profile characterized by reduced concentrations of resolvins, 
including the protective immunoresolvent PCTR1, along with elevated inflammation-
initiating eicosanoids. We found that acetylcholine upregulated the PCTR biosynthetic 
pathway in ILC3s. Administration of PCTR1 or ILC3s to vagotomised mice restored 
tissue resolution tone and host responses to E. coli infections. Together these findings 
elucidate a host protective mechanism mediated by ILC3-derived pro-resolving circuit, 
including PCTR1, that is controlled by local neuronal output to regulate tissue resolution 
tone and myeloid cell responses. 
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eTOC 
Resolution of the inflammatory response to infections is important for preventing damage 
to the host. Dalli et al. find that the vagus nerve promotes bacterial clearance by 
regulating tissue ILC3 numbers and upregulating the protective mediator PCTR1, which 
conditions peritoneal macrophage responses and promotes resolution of infection.  
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Introduction 
Progression of the acute inflammatory response is highly coordinated, and when self-
limited, leads to disposal of the inciting stimulus and re-establishment of function in 
affected organ(s) (Chiang et al., 2012; Fullerton et al., 2014; Leslie, 2015; Nathan, 2012; 
Serhan et al., 2015; Tabas and Glass, 2013; Ward, 2012). The initiation of this vital 
response is governed by diverse local signals that include cytokines, chemokines 
(Dinarello, 2011) and chemical mediators produced via stereospecific conversion of 
precursor essential fatty acids (Nakamura and Shimizu, 2011; Proia and Hla, 2015; 
Samuelsson, 2012; Serhan et al., 2015). These mediators form gradients that promote 
leukocyte recruitment to the site of injury and/or infection (Haeggstrom and Funk, 2011; 
Samuelsson, 2012). Termination or resolution of this host response is now appreciated 
to be an active process (Chiang et al., 2012; Leslie, 2015; Serhan et al., 2015) 
orchestrated by specific signals including gases (Flannigan et al., 2014), proteins (Leoni 
et al., 2015) as well as novel essential fatty acid-derived mediators (Leslie, 2015; Serhan 
et al., 2015; Tabas and Glass, 2013).  
The first of the resolution phase lipid mediators described are now grouped in 
four new families of chemical mediators termed specialized pro-resolving mediators 
(SPMs) that include resolvins, protectins, lipoxins and maresins (Serhan et al., 2015). 
SPMs are each proven agonists in the host immune system regulating both innate 
(Campbell et al., 2010; Chiang et al., 2012) and adaptive immunity (Gao et al., 2015). 
These mediators display potent actions controlling phagocyte clearance of bacterial 
infections and reduce collateral tissue injury and inflammation. Consequently, 
dysregulated production of these pro-resolving mediators is associated with disease 
onset and/or severity (Chiang et al., 2012; Dalli et al., 2015b). Given the alarming 
increase in bacterial multidrug resistance there is an urgent need for the development of 
novel strategies to clear invading bacteria without compromising the host, as immune 
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suppresssion is a major side effect of many current therapeutics (Chiang et al., 2012; 
Nathan, 2012; Ward, 2012). Thus, understanding the endogenous mechanisms that 
regulate SPM production in infections can provide insights into potential novel 
therapeutic approaches for combatting infections that may limit unwanted side effects. 
The neuronal reflex senses peripheral inflammation and coordinates the host 
response to injury and/or infection, regulating events within the initiation of inflammation 
(Pavlov and Tracey, 2012; Rosas-Ballina et al., 2011). Recently, we found that during 
acute sterile inflammation the vagal system regulates docosahexaenoic acid (DHA) 
derived pro-resolving mediators resolvin (Rv)D1, RvD3 and protectin D1(Mirakaj et al., 
2014). In this context, the role of the neural reflex in regulating resolution status of 
peripheral tissues as well as the role(s) of this reflex in promoting the resolution of 
infectious-inflammation remains of interest. Thus it is critical to gain insights into these 
processes since they may facilitate development of host-directed resolution-based 
therapeutics to help combat infections (Lee and Zeldin, 2015). For this purpose, we 
investigated the impact of vagotomy on regulating the resolution mechanisms in the 
peritoneum as well as how this influenced innate immune responses during self-
resolving Escherichia coli infections. Results from these experiments indicated that vagal 
disruption led to dysregulation of tissue retinoic acid–related orphan receptor γ t 
(RORγt)+ CD335+ Group 3 innate lymphoid cell (ILC3) numbers, resting peritoneal lipid 
mediator profiles and macrophage responses. This in turn was associated with delayed 
resolution of infectious-inflammation. Together, the present findings identify ILC3 and 
PCTR1 as central mediators in neuronal control of host response to peritoneal 
infections.  
 
 
  
	 6	
Results 
Vagotomy alters resting peritoneal lipid mediator profiles  
 Events occurring during the early phases of inflammation may have a 
profound impact on the amplitude and duration of these responses (Dalli et al., 2015a). 
SPMs orchestrate the host response to both sterile and infectious insults (Chiang et al., 
2012; Dalli et al., 2015a). To establish the role of the vagus system in regulating the 
tissue pro-resolution tone we assessed peritoneal lipid mediator (LM) profiles prior to 
infectious challenge in sham and mice subjected to resection of the right vagus trunk. 
Using liquid chromatography tandem mass spectrometry (LC-MS-MS) based LM 
metabololipidomics we identified mediators from all three major bioactive metabolomes 
in peritoneal lavages (Figure 1a, b). These included the resolvins, protectins and 
maresins from docosahexaenoic acid, E-series resolvins and the arachidonic acid 
derived lipoxins, leukotrienes (LTs), thromboxanes (TXs) and prostaglandins (PGs). 
Multivariate analysis of lipid mediator profiles obtained from sham and vagotomised mice 
at 1, 3 and 7 days post-vagotomy showed that conditions segregated into distinct 
clusters (Figure 1c). Assessment of the loading plot for these lipid mediator profiles 
demonstrated a strong association between the recently elucidated host protective 
mediator PCTR1 (16R-glutathionyl, 17S-hydroxy-4Z,7Z,10Z,12E,14E,19Z-
docosahexaenoic acid) (Dalli et al., 2015c) and sham mice with a Variable Importance in 
Projection (VIP; see methods for details) score >1. Moreover, the peritoneal PCTR1 
concentration was reduced as early as 1 day after vagotomy, with the changes reaching 
statistical significance on days 3 and 7 when compared to peritoneal lavages from sham 
mice (Figure 1c and Table 1). In these lavages, there were also significant increases in 
the concentrations of several inflammation-initiating mediators such as PGF2α compared 
to lavages from sham mice. These alterations in peritoneal lipid mediator profiles were 
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also associated with a time dependent decrease in peritoneal acetylcholine (ACh) 
concentrations following vagotomy (Figure 1d).  
Peritoneal innate immunity is dysregulated in vagotomised mice 
We next investigated whether vagotomy also led to perturbation of the resident 
peritoneal leukocyte population. In peritoneal lavages from naive mice we identified a 
cell population that was FSClow, SSClow, Lineage-, NK1.1low/-, RoRγt+, CD127+, CD117+, 
IL23R+, CD335+ that express a similar phenotypic profile to group 3 innate lymphoid cells 
(ILC-3) found in the intestinal lamina propria as well as those from spleens (Figure S1). 
To further characterize this novel ILC-3 population we sorted peritoneal ILC-3 using a 
validated gating strategy highlighted in Figure S2 that gave essentially identical cell 
numbers to that described in the literature (Robinette et al., 2015) and outlined in Figure 
S1. We then assessed the expression of a panel of genes that are upregulated in ILC-3 
when compared to NK1.1 cells (Robinette et al., 2015). Realtime PCR analysis of these 
sorted cells demonstrated that peritoneal ILC-3 expressed higher levels of II-22, Il-23r, Il-
1r1, Igfbp7 and Pram1 (Figure S3) then NK1.1 cells. When next assessed the impact of 
vagotomy on these cells and found that when mice were subjected to vagotomy there 
was a perturbation of this cell population with a significant reduction in the number of 
these cells (Figure 2a). Disruption of the right vagus also led to a time dependent 
increase in the number of peritoneal F4/80+CD11b+ macrophages (Figure 2b). Vagotomy 
did not appear to substantially change either the CD3+ T cells or CD19+B220+ B cells, 
whereas NK1.1+CD335+ natural killer (NK)-cell numbers (n=4 mice/group) were 
significantly reduced 1 day after vagotomy (1.2±0.3 x 105 cells/mouse vs 5.8±0.5 x105 
cells/mouse in vagotomised vs sham mice) with their numbers recovering by day 3 and 
remaining stable through to day 7.  
Vagotomy also led to time dependent alterations in the expression of 
macrophage phenotypic markers, including CD206 and major histocompatibility complex 
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class II (MHCII), when compared to cells from sham mice (Figure 2c and Table S1). 
Vagotomy also led to alterations in the lipid mediator profiles of peritoneal macrophages 
with a reduction in the concentrations of host protective mediators including PCTR1, 
PD1 and the lipoxin pathway marker 5,15-diHETE (Figure 2d, Table S2). Therefore 
these results demonstrate that disruption of the right vagus trunk leads to an alteration in 
the peritoneal leukocyte composition as well as macrophage phenotype. 
 
Vagotomy of the right vagus trunk delays the resolution of infectious-
inflammation 
We next tested whether these perturbations in the tissue responses impacted the 
host’s ability to clear bacterial infections. Inoculation of mice with 106 CFU E. coli 
resulted in a self-limited inflammatory response with maximal infiltration of Ly6G+CD11b+ 
neutrophils (Ψmax) occurring at ~12h (Tmax) followed by a decline (Figure 3a). Neutrophil 
numbers reached 50% of maximum (Ψ50) at ~34h (T50) giving a resolution interval (Ri), 
i.e. the difference between Tmax and T50, of ~22h. In contrast, in mice subjected to 
unilateral vagotomy of the right vagus E. coli inoculation led to a significant increase 
(11.9±0.6 x 106  vs 7.1±0.9 x 106 cells/exudate; p<0.05) in peritoneal neutrophil 
recruitment and delayed the resolution of inflammation with an increased Ri to ~32h 
(Figure. 3a). In vagotomised mice we also found a significant reduction in E. coli 
phagocytosis by exudate leukocytes (p<0.05) and increased exudate bacterial counts 
(Figure. 3b, c).  
To determine the specificity of the response elicited by the right vagus nerve in 
regulating peritoneal resolution tone we next investigated peritoneal host responses 
following resection of the left vagus nerve. Assessment of macrophage phenotypic 
markers demonstrated that vagotomy of the left nerve led to a significant reduction in the 
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expression of interleukin 10 (IL-10) and CD11b and an upregulation of cyclooxygenase 
(COX)-2, with the remaining macrophage markers being essentially unaltered (Figure 
S4a) when compared to macrophages from sham mice. Resection of the left vagus 
nerve did not lead to significant changes in peritoneal PCTR1 levels or macrophage and 
CD335+ ILC3 (Figure S4b-d) numbers. When challenged with E. coli, mice subjected to 
left vagotomy gave a maximum neutrophil infiltration (4.5 ± 0.7 x 106  vs 5.1 ± 0.3 x106 
neutrophils/exudate, left vagotomy vs sham) Ri (26 vs 27 h, left vagotomy vs sham) and 
exudate bacterial loads (1.9 ± 0.5 x 106 vs 3.6 ± 1.0 x106 CFU/exudate, left vagotomy vs 
sham) that were comparable to sham mice (Figure S4e,f). Together these results 
demonstrate that the right vagus nerve regulates peritoneal resolution tone and immunity 
during infections, whereas left vagal trunk disruption did not significantly alter innate 
immune responses to E. coli infections. Therefore we next sought evidence for 
mechanisms regulated by the right vagus nerve in regulating these host responses. 
 
PCTR1 rescues the dysregulated inflammatory response in vagotomised mice 
Having found that a reduction in peritoneal PCTR1 levels was associated with 
altered peritoneal macrophage phenotype and impaired host responses to infections and 
given the host protective actions of PCTR1 in infections (Dalli et al., 2015c; Ramon et 
al., 2016) we tested whether administration of PCTR1 could rectify the altered peritoneal 
macrophage profile. Mice were administered PCTR1 (75ng/mouse) and peritoneal 
lavages collected at 16h. Multivariate analysis of peritoneal F4/80+CD11b+ macrophage 
lineage markers demonstrated a rightward shift in the cluster representing macrophage 
profiles from vagotomised mice compared to sham macrophages (Figure 4a). 
Macrophages from vagotomised mice displayed higher expression of CD11b, F4/80 and 
T cell Immunoglobulin Mucin Protein (TIM-4). Administration of PCTR1 to vagotomised 
mice resulted in increases in several of the markers downregulated by vagus disruption 
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including inducible nitric oxide synthase (iNOS), Arginase (Arg)-1, and CD11c, resulting 
in a left ward shift in the macrophage lineage profile (Figure 4a and Table S3). This shift 
in peritoneal macrophage phenotype was associated with an improved ability of 
peritoneal macrophages to phagocytose bacteria (Figure 4b) and a reduction in several 
pro-inflammatory molecules including C-X-C motif ligand (CXCL)1 and the mouse 
homologue of interleukin 8 (KC) (n=3 mice per group; p<0.05). In addition, PCTR1 
administration also led to a shift in the peritoneal lipid mediator profile (Figure 4c and 
Table S4). Here we found a rightward shift in the LM cluster from vagotomised mice 
compared to sham mice. Administration of PCTR1 to vagotomised mice reversed this 
shift in peritoneal lipid mediator profiles following vagotomy with the resulting lipid 
mediator profile cluster giving similar co-ordinates as those obtained with sham mice. 
This leftward shift in the LM profile clusters was accompanied by an upregulation of 
several SPM known to be organ protective (Serhan et al., 2015) including AT-LXA4, 
RvD3 and PCTR3 and a downregulation of inflammation initiation eicosanoids 
(Haeggstrom and Funk, 2011; Samuelsson, 2012) such as PGD2, PGF2α and LTB4 
(Figure 4c and Table S4).  
Since PCTR1 administration rectified peritoneal macrophage responses as well 
as the peritoneal lipid mediator profile in vagotomised mice, we next tested whether this 
was sufficient to restore the host response during infections. PCTR1 given to 
vagotomised mice 16h prior to E. coli inoculation rescued the host response, significantly 
reduced neutrophil recruitment as well as shortened the resolution interval from ~36h to 
22 h. In comparison, the resolution interval was shortened to 16h when PCTR1 was 
administered to sham mice (Figure 4d). In addition, PCTR1 administration significantly 
upregulated E. coli phagocytosis by exudate leukocytes, reduced exudate bacterial 
loads and upregulated macrophage efferocytosis, key responses in the resolution of 
inflammation (Fullerton et al., 2014; Serhan et al., 2015), in both vagotomised and sham 
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mice (Figure 4e-f). Together these results demonstrate that PCTR1 rectifies peritoneal 
macrophage phenotype and host responses to E. coli infections in vagotomised mice. 
 
ILC3s regulate peritoneal macrophage production of PCTR1 and accelerate 
resolution of infectious-inflammation 
In vagotomised mice we found significant decreases in peritoneal ACh 
concentrations as well as in the production of PCTR1 by peritoneal macrophages 
(Figure 1 and 2). Given the role that these play in regulating host responses to infections 
we tested whether administration of cholinergic receptor agonists would rectify the 
macrophage phenotype and PCTR1 production. For this purpose we gave vagotomised 
mice carbachol, a muscarinic and nicotinic receptor agonist that is metabolically more 
resistant to further conversion than ACh. This upregulated the expression of 
macrophage lineage markers including COX-2, MHCII, CD11c and Arg-1 on peritoneal 
macrophages when compared to vagotomised mice (Figure 5a and Table S5). 
Carbachol administration did not significantly regulate peritoneal CD335+ ILC3 numbers 
and PCTR1 in vagotomised mice (Figure 5b,c).  
 ILC3s are central in orchestrating the host immune response to bacterial 
infections (Mortha et al., 2014), with factors produced by these cells being important in 
regulating both innate and adaptive immune responses. Given that ILC3 numbers were 
reduced in vagotomised mice, we next questioned whether loss of these cells from the 
peritoneum would reduce peritoneal PCTR1 concentrations and alter macrophage 
phenotypes. To address this, Rag1-/- mice were either given an anti-CD90.2 antibody 
(see methods), that depleted peritoneal ILC3s by ~75% (n= 6 mice; p<0.05), or an 
isotype control. After 3 days, peritoneal lavages were obtained and assessed for 
peritoneal lipid mediator profiles and macrophage phenotype. Multivariate analysis of 
lipid mediator profiles obtained from these mice resulted in distinct lipid mediator clusters 
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(Figure 5d). Assessment of the loading plot demonstrated an association between 
CD335+ ILC3 and PCTR1 (Figure 5d), with concentrations of this immunoresolvent being 
significantly reduced in mice given the anti-CD90.2 antibody when compared to mice 
given an isotype antibody (Table S6a). In mice given the anti-CD90.2 antibody we also 
found a shift in the peritoneal macrophage phenotype as demonstrated by multivariate 
analysis of phenotypic markers from these mice in comparison with macrophages from 
mice given an isotype control antibody (Figure 5e and Table S6b). 
We next tested whether these changes were associated with dysregulated host 
responses to infection. Mice administered the anti-CD90.2 antibody, showed significant 
increases in peritoneal neutrophil recruitment at each time interval, with a ~ 25% 
increase in Ψmax and delay in the resolution interval from 18 h to 25 h compared to mice 
given an isotype control antibody (Figure 5f). This reduction in peritoneal ILC3 numbers 
was also associated with a significant decrease in exudate leukocyte phagocytosis of E. 
coli, increased peritoneal bacterial load (Figure 5g,h) and increased inflammation-
initiating eicosanoids PGD2, PGE2, PGF2α ,TXB2 and LTB4 (n=4 mice per group; p<0.05). 
These results demonstrated that ILC3 depletion reduced peritoneal PCTR1 and altered 
the phenotype of peritoneal macrophages resulting in a dysregulated host response to 
infections. 
 
Acetylcholine upregulates the PCTR biosynthetic pathway in human ILC3s that 
promote resolution of bacterial infections 
Given that lipid mediators, including PCTR1, regulate macrophage phenotype 
and function (Ramon et al., 2016; Serhan et al., 2015) we next tested whether ILC3s 
controlled peritoneal macrophage responses via SPM production. We first sorted mouse 
ILC3 (~98% purity, Figure S1b) and assessed the expression of 12/15-lipoxygenase 
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(LOX), a key enzyme in pro-resolving mediator biosynthesis. Realtime qPCR (n = 3 
mice) and flow cytometric analysis of mouse CD335+ ILC3s demonstrated that these 
cells expressed the murine homologue of this enzyme (Figure 6a). In addition, realtime 
quantitative PCR analysis of these sorted cells demonstrated that they also expressed 
the cholinergic receptors Cholinergic Receptor, Muscarinic (Chrm) 1, Chrm2, Chrm4 and 
Chrm5  (n=3 mice). Incubation of CD335+ ILC3 with ACh, a key vagus derived 
neurotransmitter (Vartiainen, 1934), upregulate the levels of the PCTR1 pathway marker 
17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (17-HDHA; Figure 6b).  
We next tested whether these cells were responsible for regulating peritoneal 
macrophage PCTR1 production in vagotomised mice. Incubation of peritoneal 
macrophages with peritoneal CD335+ILC3s (sorted as illustrated in Figure S2b) resulted 
in increased PCTR1 production when compared to mice incubated with vehicle alone, 
and this action was reversed when ILC3 were incubated with a lipoxygenase inhibitor 
prior to incubation with peritoneal macrophages (Figure 6c). Given these actions we 
investigate potential sites within the peritoneum where the crosstalk between cholinergic 
nerves, ILC3s and macrophages could occur. Given the role of the greater omentum in 
leukocyte trafficking to the peritoneum (Fukatsu et al., 1996) and that the right vagus 
nerve fibers terminate in gastroepiploic plexus, the location of neural cell bodies that 
project axons in the gastroepiploic nerve that innervate this organ, (Swanson, 2015) we 
assessed whether these interactions may occur in the greater omentum. Using confocal 
microscopy we identified RoRγt+CD3- cells in close proximity to choline acetyltransferase 
positive cells and F4/80+ cells (Figure 6d). 
Since PCTR1 displays potent host protective actions we next tested whether 
adoptive transfer of ILC3 would rectify the dysregulated host response in vagotomised 
mice. To this end, we sorted mouse ILC3s from enrich splenocytes populations following 
the gating strategy illustrated in Figure S5. These cells were then adoptively transferred 
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via i.p. injection to vagotomised animals 3h prior to E. coli inoculation and resolution 
indices were calculated. ILC3 administration led to a significant decreases in neutrophil 
recruitment, shortened the resolution interval from ~38 h to ~23 h and reduced 
peritoneal bacterial loads when compared to vagotomised mice given only vehicle  
(Figure 6e, f). These protective actions were lost when ILC3s were incubated with a 
lipoxygenase inhibitor prior to administration to mice, thus supporting a role for ILC3-
derived SPMs in regulating peritoneal resolution tone and host responses to infections.  
To test whether these findings had translational relevance in humans, we next 
assessed whether human FSClowSSClowLIN-CD127+ CD161+ RORγt+CD56+CD336+/- 
ILC3s expressed 15-LOX type 1, the human homologue to mouse 12/15-LOX in the 
PCTR biosynthetic pathway. Using flow cytometry (Figure 6g, Figure S6) and real-time 
qPCR (n=4 donors) we found that human ILC3s expressed this SPM biosynthetic 
enzyme. Incubation of human ILC3s with ACh also significantly upregulated 17-HDHA 
levels (41.7±7.4 vs 113±13.1 pg/1x106 cells; ILC3 vs ILC3+Ach; p<0.01).  To further 
underpin the role of SPMs in mediating the protective actions of ILC3s and rule out the 
contribution of proteins in mediating these actions, we administered human ILC3s to 
mice 3h prior to infections. Human ILC3s were incubated with ACh and then 
administered to vagotomised mice, and this led to a significant reduction in neutrophil 
numbers in peritoneal exudates and shortening of the resolution interval from by ~10 h, 
compared to vagotomised mice given only vehicle (Figure 6h). These protective actions 
were lost when ILC3s were incubated with a lipoxygenase inhibitor prior to 
administration to vagotomised mice. Together these results demonstrate that ILC3s 
regulate peritoneal resolution tone and host responses to bacterial infections via SPMs, 
upregulating peritoneal macrophage PCTR1 levels and promoting the resolution of 
infectious-inflammation.  
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Discussion 
Results from the present report detail a resolution circuit regulated by the vagal 
system that involves pro-resolving mediators, ILC3s and resident peritoneal 
macrophages. Disruption of the vagal system lead to an alteration in the cellular 
composition of resident innate immune cells in the peritoneum as well as a shift in the 
phenotype of tissue resident macrophages. In addition, vagotomy resulted in an altered 
peritoneal lipid mediator profile with decreased in the tissue protective and 
immunoresolvent PCTR1, and increased concentrations of inflammation initiating 
eicosanoids. Vagotomy also delayed the resolution of E. coli-initiated bacterial infection. 
This delay in infection-resolution was rescued by administration of either mouse or 
human ILC3s or PCTR1, which limited neutrophil infiltration to the site of infection, 
restored peritoneal macrophage responses and enhanced the containment and 
clearance of bacteria. Together these findings indicate that ILC3s and PCTR1 are 
actively involved in regulating the tissue resolution capacity establishing a resolution 
circuit that is under the control of the central nervous system. 
Regulation of peripheral host responses to injury or infection is now appreciated 
to be under the control of the nervous system, with the efferent vagal nerve involved in 
coordinating cellular recruitment and actions at the inflamed site (Pavlov and Tracey, 
2015). Disruption of the vagal system leads to a dysregulated host response and 
disease propagation following both sterile and infectious insults (Mirakaj et al., 2014; 
Pavlov and Tracey, 2015; Rosas-Ballina et al., 2011). This regulation is in part mediated 
via the release of ACh by the vagus that regulates innate and adaptive immune cell 
responses during inflammation (Pavlov and Tracey, 2015). Recently we reported that the 
vagus also regulates resolution responses during sterile inflammation by modulating 
local levels of the neuronal guidance molecule netrin-1 as well as RvD1, RvD3 and PD1 
(Mirakaj et al., 2014). In the present study we found that the vagus also played a critical 
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role in regulating the resolution tone of the peritoneum, whereby vagotomy led to a 
significant increase in resident peritoneal macrophage numbers, a shift in their 
phenotype to a pro-inflammatory phenotype and a reduced ability to phagocytose 
bacteria. In these mice we also found a significant reduction in peritoneal ILC3 numbers 
and a shift in the peritoneal lipid mediator profile prior to challenge, with an increase in 
inflammation initiation eicosanoids and a reduction in PCTR1. In addition, vagotomy led 
to a disruption of resolution responses to pathogenic E. coli characterized by increased 
leukocyte recruitment, exudate inflammatory eicosanoids at the peak of inflammation (n 
= 5-6 mice per group; p<0.05), a reduction in the ability of exudate leukocytes to 
phagocytose bacteria and a delay in the resolution of infectious inflammation.  
Tissue resident cells provide the first line of defense against infections with 
innate cells paying a critical role in initiating the inflammatory response (Kim and Luster, 
2015). In the peritoneum, resident macrophages are key players in orchestrating the 
initiation of the inflammatory response. Upon recognition of an inflammatory stimulus 
(e.g. bacteria) these cells produce a host of inflammatory signals including cytokines and 
lipid mediators that lead to vascular leakage and leukocyte recruitment (Hellmann et al., 
2015). In addition, these cells also actively participate in clearance of invading 
pathogens and alteration in their phenotype impairs their ability to clear bacteria and 
leads to a dysregulated inflammatory response in experimental systems (Dahdah et al., 
2014) and humans (Ahmed et al., 2014). In the present study we found that 
administration of PCTR1 to vagotomised mice 16h prior to challenge at a dose as low as 
75ng/mouse restored the macrophage phenotype as well as phagocytic function. In 
addition, this immunoresolvent also rectified the dysregulated peritoneal resolution 
responses in vagotomised mice indicating a central role for PCTR1 in regulating the 
resolution tone in this tissue and in promoting the resolution of infectious-inflammation.  
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It is now appreciated that tissue resident ILC3s actively regulate macrophage 
responses in infections via the production of cytokines such as. GM-CSF (Mortha et al., 
2014). In the present experiments, we found that murine and human ILC3 expressed the 
initiating enzyme in the production of PCTR1 and that incubation of ILC3s with ACh led 
to an increase in 17-HDHA, the biosynthetic pathway marker in the PCTR metabolome. 
In this context the actions of ACh on ILC3 may have been mediated by at least one of 
the cholinergic receptors Chrm1, Chrm2, Chrm4 and Chrm5 expressed by these cells. 
Depletion of ILC3s in Rag1-/- mice led to a dysregulated peritoneal lipid mediator profile, 
a reduction in PCTR1 concentrations, an alteration of the peritoneal macrophage 
phenotype and a delay in the resolution of infectious inflammation. Administration of 
human or mouse ILC3s prior to bacterial infection restored resolution responses in 
vagotomised mice, an action that was inhibited when these cells were pre-incubated with 
a lipoxygenase inhibitor.  These results demonstrated that ILC3s carry the biosynthetic 
machinery necessary for the production of pro-resolving mediators. They also 
demonstrated that ACh, a central mediator in the vagal response, regulates the PCTR 
biosynthetic pathway in ILC3s that may in turn regulate resident peritoneal macrophage 
responses.  
Therefore several lines of evidence were employed to determine the role of the 
right vagus in controlling peritoneal resolution tone and host responses to infections via 
ILC3 and PCTR1. They are as follows: i) vagotomy reduced peritoneal PCTR1 levels 
prior to bacterial challenge; ii) Resection of the right vagus trunk reduces peritoneal ILC3 
counts and alters peritoneal macrophage phenotype; iii) vagotomized mice had an 
exacerbated inflammatory response, delayed resolution and in efficient bacterial 
clearance in response to E. coli infections; iv) peritoneal macrophage derived PCTR1 
accounted for ~ 70% of peritoneal PCTR1 levels in sham mice; v) PCTR1 administration 
to vagotomised mice restored peritoneal macrophage phenotype and responses to 
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infection and partially rescued the peritoneal lipid mediator profile; vi) Administration of 
carbachol, a nicotinic and muscarinic agonist, to vagotomized mice did not restore 
peritoneal ILC3 numbers and PCTR1 levels and only partly restored peritoneal 
macrophage phenotype;.vii) ILC3 depletion in Rag1-/- mice gave reduced peritoneal 
PCTR1, alteration of the resident peritoneal macrophage phenotype and delayed 
resolution responses to infection; viii) ILC3 express the initiating enzyme in the PCTR1 
biosynthetic pathway and incubation of ILC3 with acetylcholine upregulated the PCTR1 
pathway; ix) ILC3, macrophages and cholinergic cells are found in close proximity in the 
greater omentum; x) Incubation of peritoneal macrophage from vagotomised mice with 
ILC3 upregulated macrophage PCTR1 production, an action that was reversed when 
ILC3 we incubated with a lipoxygenase inhibitor xi) Addback of human and mouse ILC3 
restored host responses to E. coli infections in vagotomized mice, protective actions that 
were lost when ILC3 were incubated with a lipoxygenase inhibitor. 
In summation, the present results identify neural-regulated ILC3 pro-resolving 
mediator production that contributes to maintaining local homeostatic tissue tone and 
expedites resolution of bacterial infections. These results elucidate a mechanism for 
peripheral neuronal control in regulating ILC3 responses and PCTR1 production that 
orchestrate host responses during infections. Thus these results indicate that impairment 
of the cholinergic system, as for example found in aging, diminishes pro-resolving 
mediator production by resident leukocytes leading to an altered tissue resolution tone 
and blunted resolution responses to infectious challenge. These findings may be useful 
in designing therapeutics for treating infectious-inflammation that spares the immune 
response.  
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Experimental Procedures  
E. coli peritonitis 
All animal experiments were conducted in accordance with the Harvard Medical Area 
Standing Committee on Animals (protocol no. 02570) and UK Home Office regulations 
(Guidance on the Operation of Animals, Scientific Procedures Act, 1986). Mice (male 
FvB, 6-8 weeks old, Charles River, fed lab diet containing essential fatty acids as from 
supplier) were anesthetized and cervical vagotomy or sham surgery were performed 7 
days before induction of peritonitis (Mirakaj et al., 2014). In brief, mice were anesthetized 
and a ventral cervical midline incision was performed to expose the right cervical vagus 
trunk, which was ligated with a 4.0 silk suture and then divided. 1, 3 or 7 days later, 
peritoneal lavages and organ tissues were obtained. In select experiments 7 day after 
vagotomy peritonitis was initiated by intraperitoneal injection of E. coli (serotype 
O6:K2:H1; 1x106 CFU/mouse). At designated time intervals mice were harvested, blood 
was collected via cardiac puncture in heparin, and peritoneal exudates were collected by 
injecting in 4ml of PBS intraperitoneally and ~ 3ml of PBS were recovered. The cellular 
composition in the exudates was determined using Turks solution and light microscopy, 
and flow cytometry.  For flow cytometry, exudate cells were incubated with anti-mouse 
CD16/CD32 (eBiosciences, 20min, 4oC, in PBS containing 5% fetal calf serum-staining 
solution), followed by incubation with lineage specific markers for 30min (4oC, in staining 
solution). Cell counts for each population were then calculated by multiplying the total 
cell counts obtained using light microscopy and the percentage of each population as 
determined by flow cytometry and the normalized to 4ml of PBS that was initially 
injected. 
 
Flow cytometry  
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Mouse cells were incubated with anti-mouse CD16/CD32 (eBiosciences, 20min, 4°C, in 
PBS containing 5% fetal calf serum-staining solution), followed by incubation with 
lineage specific markers for 30min (4oC, in staining solution), all antibodies were 
purchased from BioLegend unless otherwise stated. Multiparameter analysis was 
performed on FACS Canto II (BD), BD LSR Fortessa and BD FACSAria II and analysis 
was conducted using FlowJo (Tree Star). For staining of intracellular components we 
incubated cell with Foxp3-staining kit (eBioscience) according to the manufacturer’s 
instructions prior to addition of fluorescently labeled antibodies. Dead cells were 
excluded using LIVE/DEAD Fixable Yellow Dead Cell Stain (Invitrogen, Carlsbad, CA). 
For neutrophil analysis the following antibodies were employed: PE-anti-Ly6G (clone: 
1A8), PE/Cy5.5-anti-CD11b (clone: M1/70). For macrophage phenotypic analysis we 
used the following antibodies: PE-Cy7-anti-CD11b (clone: M1/70), Brilliant Violet (BV) 
650-anti MHCII (clone: M5/114.15.2) APC-Cy7-anti-F4/80 (clone: BM8), PE-Dazzle 594-
anti-IL10 (clone: JES5-16E3), BV-421-anti-TGFβ (clone: TW7-16B4), BV785-anti-CD11c 
(clone: N418), Alexa-647-anti-Tim4 (clone: F31-5G3), FITC-anti-COX-2 (Cayman 
Chemicals; Cat no: 10010096), PE-anti-Arg-1 (R&D Systems, Cat no: IC5868P), Alexa 
Fluor 488-anti-iNOS (clone: CXNFT). 
For T-cell analysis the following antibody was used: FITC-anti-CD3 (clone: 
17A2). For B-cell analysis the following antibodies were used PE-anti-CD19 (clone: 6D5) 
and APC-anti-B220 (clone: RA3-6B2). ILC3 populations were determined using the 
following antibodies: FITC-anti-CD3 (clone: 17A2), FITC-anti-CD19 (clone: 6D5), FITC-
anti-CD11c (clone: N418), FITC-anti-Ly6G (clone: 1A8), FITC-anti-F4/80 (clone: BM8), 
FITC-anti-CD14 (clone: Sa14-2), Alexa Fluor 647-anti-RORγt (clone: Q31-378; BD 
Pharmingen), BV711-anti-NK1.1 (clone: PK136), BV650-anti-CD127 (clone: A7R34), 
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PE-anti-IL23R (clone: 753317; R&D Systems), PE-Cy7-anti-CD117 (clone: 2B8; 
BioLegend) and BV421-anti-CD335 (clone: 29A1.4). 
 
ILC3 fluorescence-activated cell sorting 
For sorting of human ILC3 blood peripheral blood mononuclear cells (PBMC) 
were purchased from Children’s Hospital Blood Bank, Boston and cells enriched using 
an EasySepTM Human NK cell enrichment kit (Stemcell Technologies) following 
manufacturers instructions. Subsequently cells were incubated with LIVE/DEAD Fixable 
Yellow Dead Cell Stain (Invitrogen) following manufactures instruction then with the 
following antibody combination: FITC-anti-CD3 (clone:	UCHT1), FITC-anti-CD19 (clone: 
HIB19, FITC-anti-CD14 (clone: HCD14), FITC-anti-CD20 (clone: 2H7), FITC-anti-CD1a 
(clone: HI149), FITC-anti-CD34 (clone: 581), FITC-anti-TCR α/β (clone: IP26), FITC-
anti-CD94 (clone: DX22), PE-Cy7-anti-CD161 (clone: HP-3G10), BV711-anti-CD117 
(clone: 104D2), PE-CF594-anti-CD294 (clone: BM16; BD Bioscience) and eFluor450-
anti-CD336 (clone: 44.189; eBioscience). In select experiments sorted cells were 
incubated with Foxp3-staining kit (eBioscience) according to the manufacturer’s 
instructions and then Alexa Fluor-647-anti-RORγt (clone: Q21-559; BD Bioscience), or 
with an Alexa Fluor-647-anti-15-LOX-1 (Bioss: cat no: bs-6505R-A647). 
For sorting of mouse cells, spleens were gently dispersed using a 70µm strainer, 
cells were then enriched using an EasySepTM MouseNK cell enrichment kit (Stemcell 
Technologies) following manufacturers instructions. Subsequently cells were incubated 
with LIVE/DEAD Fixable Yellow Dead Cell Stain (Invitrogen) following manufactures 
instruction then with the following antibody combination: FITC-anti-CD3 (clone: 17A2), 
FITC-anti-CD19 (clone: 6D5), FITC-anti-CD11c (clone: N418), FITC-anti-Ly6G (clone: 
1A8), FITC-anti-F4/80 (clone: BM8), FITC-anti-CD14 (clone: Sa14-2), BV711-anti-NK1.1 
(clone: PK136), BV510-anti-CD127 (clone: A7R34), PE-anti-IL23R (clone: 753317; R&D 
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Systems) and BV421-anti-CD335 (clone: 29A1.4). In select experiments sorted cells 
were incubated with Foxp3-staining kit (eBioscience) according to the manufacturer’s 
instructions and then with an anti-15-LOX-1 (Bioss: cat no: bs-6505R) then with an Alexa 
Fluor-647-anti-15-LOX-1 (Bioss: cat no: bs-6505R-A647). 
 
Lipid mediator profiling 
Peritoneal lavages and infectious exudates were placed in 2 volumes of ice-cold 
methanol. Samples for LC-MS-MS-based metabololipidomics were extracted with solid-
phase extraction columns (Colas et al., 2014). Briefly, prior to sample extraction, 
deuterated internal standards (d4-PGE2, d5-LXA4, d4-RvD2, d4-LTB4, d5-LTC4, d5-LTD4, 
d5-LTE4 and d8-5S-HETE) representing regions of interest in chromatographic analysis 
(500 pg each) were added to facilitate quantification. Eluted methyl formate fractions 
were analyzed by a LC-MS-MS system, Qtrap 5500 (AB Sciex) equipped with a 
Shimadzu SIL-20AC autoinjector and LC-20AD binary pump (Shimadzu Corp.). An 
Agilent Eclipse Plus C18 column (100x4.6mmx1.8µm) was used with a gradient of 
methanol/water/acetic acid of 55:45:0.01 (vol:vol:vol) that was ramped to 85:15:0.01 
(vol:vol:vol) over 10 min and then to 98:2:0.01 (vol:vol:vol) for the next 8 min. This was 
subsequently maintained at 98:2:0.01 (vol:vol:vol) for 2 min. The flow rate was 
maintained at 0.4ml/min. To monitor and quantify the levels of lipid mediators, a multiple 
reaction monitoring (MRM) method was developed with signature ion fragments (m/z) for 
each molecule monitoring the parent ion (Q1) and a characteristic daughter ion (Q3). 
Identification was conducted using published criteria where a minimum of 6 diagnostic 
ions were employed (Colas et al., 2014). Calibration curves were determined using a 
mixture of lipid mediators obtained via total organic synthesis. Linear calibration curve 
for each compound was obtained with r2 values ranging from 0.98 to 0.99. Detection limit 
was ~0.1 pg. Quantification was carried out as in (Colas et al., 2014).  
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For identification and quantification of PCTRs and cysteinyl leukotrienes, 
methanol fractions were taken to the LC-MS-MS system operated as described (Dalli et 
al., 2015c) with minor modifications. A Shimadzu LC-20AD HPLC and a Shimadzu SIL-
20AC autoinjector paired with a QTrap 5500 (AB SCIEX) were used. A Poroshell 120 
EC-C18 column (100 mm × 4.6 mm × 2.7 µm; Agilent) was kept in a column oven at 50 
°C (Therma Sphere; TS-130), and lipid mediators were eluted with a mobile phase 
consisting of methanol/water/acetic acid at 55:45:0.1 (vol:vol:vol) that was isocratic for 1 
min, ramped to 70:30:0.1 (vol:vol:vol) over 5 min, then to 80:20:0.1 (vol:vol:vol) for 2 min, 
then isocratic 80:20:0.1 (vol:vol:vol) for the next 3 min, and ramped to 98:2:0.1 
(vol:vol:vol) over 3 min. This was subsequently maintained at 98:2:0.1 (vol:vol:vol) for 3 
min, and the flow rate was maintained at 0.6 ml/min. The QTrap 5500 was operated in 
positive ionization mode using scheduled multiple reaction monitoring (MRM) coupled 
with information-dependent acquisition and enhanced product ion scan. For complete 
chemical nomenclature for the SPM and other lipid mediators identified herein, see 
(Colas et al., 2014; Dalli et al., 2015c). 
 
Macrophage incubations 
Peritoneal macrophages from sham, vagotomised mice and vagotomised mice given 
PCTR1 were collected in 4 ml of DPBS (without calcium and magnesium), cells were 
counted and seeded (5x104 cells/well) in 96 well plates and allowed to adhere for 2h at 
37oC. Non-adherent cells were washed and cells incubated with fluorescently labeled 
bacteria and phagocytosis was assessed using a Zeiss YFL (Carl Zeiss, Thornwood, 
NY, USA) and ImagePro Plus 7 software (Media Cybernetics, Bethesda, MD, USA) and 
SpectraMax M3 plate reader (Molecular Devices Inc, Sunnyvale, CA) and results 
analyzed using SoftMax Pro (Molecular Devices Inc, Sunnyvale, CA)(Chiang et al., 
2012). 
	 24	
In select experiments macrophages (2x105 cells/well) were plated in 12 well plates, 
incubated for 2h at 37oC to allow for adhesion, non-adherent cells were washed off and 
cells incubated with E. coli (1x107 CFU/well) for 6h at 37oC. Supernatants were then 
collected and centrifuged at 10,000xg for 10 min to remove any cellular debris and 
cytokine levels were assessed using a Proteome Profiler™ Mouse XL Cytokine Array Kit 
(R&D systems) following manufacturers instructions. 
In separate experiments macrophages from sham or vagotomised mice 1, and 7 days 
post vagotomy were plated in 6 well plates (1x106 cells/well, 45 min, 37oC, PBS+/+). Cells 
incubations were quenched using ice-cold methanol containing deuterium labeled 
internal standards and lipid mediators identified and quantified as detailed above.  
To investigate whether CD335+ ILC3 regulate macrophage responses, macrophages 
were isolated from vagotomised mice 2 days post vagotomy, cells were plated in 6 well 
plates (1x106 cells/well, 45 min, 37oC, PBS+/+). Non-adherent cells were removed and 
cells incubated with CD335+ ILC3 (7.5x102 cells/well, 6h, 37oC, PBS+/+, 2% FCS). 
Incubations were quenched using ice-cold methanol containing deuterium labeled 
internal standards and PCTR1 was identified and quantified as detailed above.  
 
Statistics 
All results are expressed as means ± SEM. We assumed normality and equal 
distribution of variance between the different groups analyzed. The experiments were 
conducts and analysed using a factorial design. Differences between groups were 
compared using Student's t test (2 groups), 1-way ANOVA and 2-way ANOVA (multiple 
groups) followed by post hoc Bonferroni test. Investigators were not blinded to group 
allocation or outcome assessment. Sample sizes for each experiment were determined 
on the variability observed in preliminary experiments and prior experience with the 
experimental systems. The criterion for statistical significance was p<0.05. PLS-DA 
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analysis was conducted using SIMCA 13.0.3 software (Umetrics, San Jose, CA) as 
described in (Colas et al., 2014) with mediators and macrophage lineage markers giving 
Variable Importance in Projection scores greater than 1 taken as displaying significant 
correlation. This parameter estimates the importance of a variable in the Partial Least 
Square projections with scores greater then 1 indicating that a specific variable is 
important in a given model. 
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Figure Legends 
Figure 1: Vagotomy diminishes PCTR1 concentrations and elevated eicosanoids 
in peritoneum. 
 Mice were subjected to right unilateral vagotomy or sham surgery, at the indicated 
intervals the peritoneal cavity was lavaged and lipid mediators profiled using LC-MS-MS 
based LM metabololipidomics (see methods for details). (a) Representative multiple 
reaction chromatograms for identified lipid mediators, and (b) MS-MS spectrum 
employed in the identification of PCTR1. (c) Lipid mediator profiles were then 
interrogated using Partial least square discriminant analysis (PLS-DA). Top panel: 2D 
score plot bottom panel: 2D loading plot. (d) Peritoneal acetylcholine levels. Results for 
a-c are representative of n=5-6 mice per group from two distinct experiments. Results for 
d are mean ± s.e.m. n=4-5 mice per group **p<0.01 vs Sham mice. m/z = mass to 
charge ratio. 
 
Figure 2: Resident peritoneal ILC3 numbers are reduced and peritoneal 
macrophage phenotype is altered in vagotomised mice. Mice were subjected to 
unilateral vagotomy or sham surgery, and peritoneal cells were collected at the indicated 
intervals. (a) ILC3 and (b) macrophage numbers were determined using light microscopy 
and flow cytometry. (c) Peritoneal macrophage phenotypic marker expression was 
determined using flow cytometry and results interrogated using PLS-DA. Top panel: 2D 
score plot bottom panel: 2D loading plot. (d) Peritoneal macrophages were isolated and 
lipid mediators determined using lipid mediator profiling. Results were then interrogated 
using PLS-DA. Top panel: 2D score plot bottom panel: 2D loading plot. Results for a, b 
are mean ± s.e.m. 4-5 mice per group from two distinct experiments. Results for c, d are 
representative of 3-4 mice per group. Related to Figure S2, S3 and Table S1, S2 
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Figure 3: Vagotomy delayed resolution of infections. Mice were subjected to 
unilateral vagotomy or sham surgery; after 7 days E. coli (1x106 CFU/mouse) were 
administered via i.p. injection. Inflammatory exudates were collected at the indicated 
intervals: (a) cell counts determined using light microscopy and flow cytometry and 
resolution indices calculated. (b) Exudate leukocyte phagocytosis of E. coli (CD11b+ E. 
coli+ cells) was determined by flow cytometry in 12h exudates (c) 12h exudate bacterial 
loads. Results are mean ± s.e.m. n= 4 mice per group from two distinct experiments. 
Related to Figure S3 
 
Figure 4: PCTR1 restores resolution responses in vagotomised mice during 
bacterial infections. (a-c) Mice were subjected to unilateral vagotomy or sham surgery, 
after 7 days vagotomised mice were administered vehicle (saline containing 0.01% 
EtOH) or PCTR1 (75ng/mouse) via i.p. injection. After 16h (a) peritoneal lavages were 
collected and macrophage phenotype was determined using flow cytometry and (b) 
peritoneal LM profiles were determined using LM metabololipidomics. (c) peritoneal cells 
were collected, plated in 96-well plates (5x104 cells/well; DPBS; 2h; 37oC) then 
incubated with fluorescently labeled E. coli (2.5x106 CFU/well; 37oC, PBS+/+, pH 7.45, 40 
min) and phagocytosis assessed using a fluorescence microscopy. Results are 
representative of n= 5-6 mice per group from two distinct experiments. (d-g) Mice were 
administered E. coli (1x106 CFU/mouse, i.p.), (d) exudates collected at the indicated 
intervals and neutrophil count determined using flow cytometry and light microscopy.  
(e) 12h Exudate leukocyte E. coli phagocytosis determined as CD11b+ E. coli+ cells, (f) 
12h exudate bacterial loads and (g) 24h exudate macrophage efferocytosis determined 
as F4/80+ Ly6G+ cells. Results for c are mean±s.e.m. n= 5-6 mice per group from two 
distinct experiments. Related to Table S3 and S4 
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Figure 5: ILC3 regulate peritoneal macrophage phenotype, PCTR1 production and 
resolution of infectious-inflammation.  Mice were subjected to right unilateral 
vagotomy or sham. Vagotomised mice were then administered vehicle (Vagotomy; PBS) 
or Carbachol (Vagotomy+Carbachol; 0.1mg/Kg/day for 7days). Peritoneal lavages were 
collected (a) expression of macrophage phenotypic markers (b) CD335+ ILC3 and (c) 
PCTR1 levels determined. Results for a are representative of n=3 mice per group. 
Results for b,c are mean±sem of n=3 mice per group. * p<0.05. (d-e) Rag1-/- mice were 
administered an anti-CD90.2 (250µg/mouse) or Isotype control (250µg/mouse) antibody, 
(d) peritoneal lavages were collected and lipid mediator profiles determined using LC-
MS-MS based LM metabololipidomics and PLS-DA. Left panel 2D score plot, right panel 
2D loading plot. (e) Peritoneal macrophages were collected and phenotypic marker 
expression determined using flow cytometry. Left panel 2D score plot, right panel 2D 
loading plot. Results are representative of n= 4 mice per group from two distinct 
experiments. (f-h)  Rag1-/- mice were administered an anti-CD90.2 (250µg/mouse) or 
Isotype control (250µg/mouse) antibody. After 3 days they were given E. coli (1x105 
CFU/mouse) via i.p. injection, exudates collected at the indicated intervals and (f) cell 
counts were determined using light microscopy and flow cytometry and resolution 
indices calculated. (g) Exudate leukocyte phagocytosis of E. coli (CD11b+ E. coli+ cells) 
was determined by flow cytometry in 12h exudates. (h) 12h exudate bacterial loads. 
Results are mean ± s.e.m. n= 4 mice per group from two distinct experiments. Related to 
Table S6 
 
Figure 6: Acetylcholine upregulates SPM biosynthetic pathways in human and 
mouse ILC3 that restore peritoneal host responses to infections in vagotomised 
mice. (a) Expression of mouse 12/15-LOX in mouse CD335+ ILC3 (b) mouse ILC3 were 
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isolated using FACS sorting (see methods) then incubated with DHA (300ng/ml) then 
with ACh (1nM, 37oC, PBS+/+, pH 7.45, 60 min). Incubations were then quenched and 
17-HDHA levels assessed using LM metabololipidomics. Results for a are representative 
of n = 3 mice. Results for b are mean ± s.e.m. n=3 mice per group. (c) peritoneal 
macrophages (Mφ; 1x106 cells/well) from vagotomised mice were incubated with 
mCD335+ ILC3 (7.5x102 cells/well, 6h, 37oC, PBS+/+, 2%FBS). Incubations were 
quenched and PCTR1 levels determined using lipid mediator profiling. Results are 
mean±sem n=3 mice per group. *p<0.05 vs  Mφ; #p< 0.05 vs  Mφ plus ILC3. (d) omenta 
were isolated from naive mice and stained for choline acetyltransferase (red), CD3 
(green), F4/80 (cyan) and RoRγt (white) and staining was imaged using confocal 
microscopy (see methods for details). Magnification x 40. Results are representative of 
n-4 mice. (e) Mice were subjected to unilateral vagotomy surgery, after 7 days they were 
administered vehicle, CD335+ ILC3 (5x102 cells), DHA (1µM) plus ACh (1nM) or CD335+ 
ILC3 (5x102 cells), DHA (1µM), ACh (1nM) plus Lipoxygenase Inhibitor (10µM; L.I.; see 
methods for details) 3 h prior to E. coli (1x106 CFU/mouse). At the indicated intervals 
leukocytes were collected and neutrophil counts determined by light microscopy and 
flow cytometry. (f) Exudate bacterial loads 12h post E. coli inoculation. Results are mean 
± s.e.m. n= 4 mice per group from two distinct experiments.  (g) Human ILC3 expression 
of 15-lipoxygenase type I (15-LOX) was determined using flow cytometry. Results for a 
are representative of n = 4 donors. (h) Mice were subjected to unilateral vagotomy 
surgery, after 7 days they were administered vehicle, ILC3 (1x103 cells), DHA (1µM), 
plus ACh (1nM) or ILC3 (1x103 cells), DHA (1µM), ACh (1nM) plus Lipoxygenase 
Inhibitor (10µM; L.I.; see methods for details) 3 h prior to E. coli (1x106 CFU/mouse; see 
methods for details). At the indicated intervals leukocytes were collected and neutrophil 
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counts determined by light microscopy and flow cytometry. Results are mean ± s.e.m. n= 
6 mice per group from two distinct experiments. 
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Table 1. Vagotomy alters the peritoneal lipid mediator profile.  
 
 
 
   Lipid mediators levels (pg/lavage)    
DHA bioactive 
metabolome Q1 Q3 Sham Day 1 Day 3 Day 7 
RvD1 375 141 2.5 ± 1.7 5.0 ± 4.7 0.2 ± 0.2 2.0 ± 0.8 
RvD2 375 141 3.4 ± 1.9 84.0 ± 23.3 0.4 ± 0.0 1.2 ± 0.1 
RvD3 375 147 0.1 ± 0.2  *   *   *  
RvD4 375 101 1.3 ± 1.0 5.9 ± 3.6 0.9 ± 0.2 1.4 ± 0.4 
RvD5 359 199 16.3 ± 8.4 35.8 ± 8.1 3.4 ± 1.9 7.5 ± 2.0 
RvD6 359 101 1.7 ± 1.5 2.9 ± 1.4 0.2 ± 0.1 0.3 ± 0.1 
17R-RvD1 375 141 0.5 ± 0.4 5.5 ± 3.8  *   *  
17R-RvD3 375 147 0.3 ± 0.3 1.3 ± 0.9 0.1 ± 0.1 0.1 ± 0.1 
               
PD1 359 153 27.5 ± 14.2 45.1 ± 14.2 11.1 ± 3.6 19.4 ± 5.4 
17R-PD1 359 153 22.9 ± 12.7 39.5 ± 6.9 10.4 ± 3.5 20.7 ± 6.8 
10S,17S-diHDHA 359 153 218.9 ± 136.8 1057.1 ± 232.6 61.8 ± 19.2 170.7 ± 49.7 
               
PCTR1 650 231 15.3 ± 4.5 2.9 ± 1.7 1.1 ± 0.2 2.8 ± 1.3 
PCTR2 521 231 12.4 ± 5.9 6.5 ± 5.7 1.2 ± 0.1 3.1 ± 1.2 
PCTR3 464 231 9.8 ± 6.2 0.2 ± 0.1  *  0.1 ± 0.1 
               
MaR1 359 221 0.3 ± 0.3  *  0.4 ± 0.1 1.2 ± 0.4 
7S,14S-diHDHA 359 221 26.5 ± 16.3 755.4 ± 144.4 10.4 ± 9.4 8.3 ± 1.6 
4S,14S-diHDHA 359 101 36.6 ± 31.8 167.3 ± 60.2 1.6 ± 0.6 8.5 ± 2.3 
               
EPA bioactive 
metabolome               
RvE1 349 195 2.2 ± 0.7 4.9 ± 1.9  *  0.4 ± 0.3 
RvE2 333 199 1.3 ± 0.7 7.0 ± 1.7 0.3 ± 0.3 0.6 ± 0.4 
RvE3 333 201 1.0 ± 0.8 1.5 ± 0.9 0.1 ± 0.1 0.4 ± 0.1 
               
AA  bioactive 
metabolome               
LXA4 351 217 0.2 ± 0.1 5.7 ± 1.7 0.1 ± 0.1 0.1 ± 0.1 
LXB4 351 221 2.7 ± 1.4 36.2 ± 13.2  *  0.6 ± 0.2 
5S,15S-diHETE 335 235 116.7 ± 67.1 1255.9 ± 362.4 18.2 ± 9.3 42.2 ± 14.2 
15R-LXA4 351 217 3.5 ± 2.4 151.9 ± 64.0 1.6 ± 0.3 3.1 ± 0.6 
15R-LXB4 351 221 4.4 ± 3.0 4.8 ± 1.8 2.2 ± 0.5 2.5 ± 0.6 
               
LTB4 335 195 25.8 ± 9.8 246.8 ± 128.1 4.9 ± 1.7 13.4 ± 4.2 
5S,12S-diHETE 335 195 34.0 ± 25.4 406.7 ± 93.1 1.3 ± 0.7 4.0 ± 2.7 
20-OH-LTB4 351 195 0.1 ± 0.1 0.3 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 
               
LTC4 626 189 70.2 ± 20.3 12.4 ± 4.0 10.5 ± 3.6 23.2 ± 10.4 
LTD4 497 189 30.3 ± 18.1 22.9 ± 11.9 11.2 ± 3.4 27.7 ± 14.1 
LTE4 440 189 11.1 ± 6.7 0.7 ± 0.3 0.9 ± 0.4 0.8 ± 0.2 
               
PGD2 351 189 50.3 ± 30.1 230.1 ± 82.4 16.8 ± 4.7 32.3 ± 12.0 
PGE2 351 189 117.9 ± 37.7 194.6 ± 69.8 61.6 ± 22.0 163.2 ± 83.9 
PGF2α 353 193 33.4 ± 14.4 72.1 ± 12.0 26.2 ± 18.1 30.0 ± 9.9 
TxB2 369 169 95.1 ± 34.0 52.3 ± 31.7 60.8 ± 7.3 101.9 ± 32.8 
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Mice were subjected to vagotomy or sham procedure, peritoneal lavages were collected 
at the indicated intervals and LM levels were assessed using LM-metabololipidomics. 
Results are expressed as pg/lavage; mean ± s.e.m.; n = 3-5 mice per group. ♯ p < 0.05  
vs Sham, * = below limit, limit ≈ 0.1 pg. With Q1, M-H (parent ion); and Q3, diagnostic 
ion in the MS-MS (daughter ion). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 		Robinette,	M.L.,	Fuchs,	A.,	Cortez,	V.S.,	Lee,	J.S.,	Wang,	Y.,	Durum,	S.K.,	Gilfillan,	S.,	Colonna,	M.,	and	Immunological	Genome,	C.	(2015).	Transcriptional	programs	define	molecular	characteristics	of	innate	lymphoid	cell	classes	and	subsets.	Nat	Immunol	16,	306-317.		
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